AstraZeneca (LON:AZN) Earns “Buy” Rating from Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Financial Group in a research note issued to investors on Wednesday, Digital Look reports. They currently have a £175 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective would indicate a potential upside of 47.95% from the company’s current price.

A number of other analysts also recently weighed in on AZN. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research report on Wednesday, September 2nd. Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Finally, Berenberg Bank restated a “buy” rating and issued a £160 price objective on shares of AstraZeneca in a report on Thursday, September 3rd. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of £151.14.

AstraZeneca Trading Down 0.4%

Shares of AZN stock opened at £118.28 on Wednesday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The business has a 50-day moving average price of £124.79 and a two-hundred day moving average price of £136.10. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32. The firm has a market cap of £183.44 billion, a P/E ratio of 17.71, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.